Morning vs evening dosing with doxazosin in benign prostatic hyperplasia: Efficacy and safety

Prostate Cancer and Prostatic Diseases

Volumn 1, Issue 3, 1998, Pages 163-171

  Kirby, R S ^a   Chapple, C R ^b   Sethia, K ^c   Flannigan, M ^d   Milroy, E J G ^e   Abrams, P ^f  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c NORFOLK AND NORWICH HOSPITAL   (United Kingdom)

^d BRADFORD ROYAL INFIRMARY   (United Kingdom)

^e MIDDLESEX HOSPITAL   (United Kingdom)

^f SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Dosing schedule; Doxazosin

Indexed keywords

EID: 0000233553     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500220     Document Type: Article

References (26)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-471.
3. Gup DI, Shapiro E, Baumann M, Lepor H. Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate 1989; 15: 105-114.
4. Lepor H et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-1474.
5. Guidelines Sub-Committee. 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension Meeting. J Hypertens 1993; 11: 905-918.
6. Joint National Committee. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1993; 153: 154-183.
7. Chappie CR et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-56.
8. Jardin A, Bensadoun H, Delauche-Cavalier MC, Attali P. Alfuzosin for treatment of benign prostate hypertrophy. Lancet 1991; 337: 1457-1461.
9. Fawzy A et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-109.
10. The third international consultation on benign prostatic hyperplasia (BPH). Monaco, June 26-28, 1995. Proceedings. ATK Cockett, S Khoury, Y Aso, C Chatelain, L Denis, K Griffiths, G Murphy, Eds.
11. Agency for Health Care Policy and Research. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline. AHCPR Publications: Silver Spring, 1995.
12. 1c-adrenoceptor: functional characterisation in prostate. Br J Pharmacol 1992; 107: 327P.
13. Christensen MM et al. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol 1993; 27: 39-44.
14. Janknegt RA, Chapple CR. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Eur Urol 1993; 24: 319-326.
15. Bendix-Holme J et al. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand J Urol Nephrol 1994; 28: 77-82.
16. Gillenwater JY et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-115.
17. Vashi V, Chung M, Dias N Phillips K. Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers J Clin Pharmacol 1996; 36: 325-331.
18. Kaplan SA, Soldo KA, Olsson CA. Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: a pilot study. Urology 1994; 44: 348-352.
19. Kaplan SA, Soldo KA, Olsson CA. Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 1995; 28: 223-228.
20. Caine M, Pfau A, Perlberg S. The use of alpha-1 adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255-263.
21. 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1990; 144: 1393-1397.
22. Jonler M, Riehmann M, Bruskewitz RC. Benign prostntic hyperplasia. Current pharmacological treatment. Drugs 1994; 47: 66-81.
23. Khoury AF, Kaplan NM. Alpha-blocker therapy of hypertension: an unfulfilled promise. JAMA 1991; 266: 394-398.
24. Lepor H. Nonoperative management of benign prostatic hyperplasia. J Urol 1989; 141: 1283-1289.
25. Lepor H et al. Doxazosin in benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525-530.
26. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 1995; 29: 7-12.